Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective

Immuno-oncologics (IOs) differ from chemotherapies as they prime the patient’s immune system to attack the tumor, rather than directly destroying cancer cells. The IO mechanism of action leads to durable responses and prolonged survival in some patients. However, providing robust evidence of the lon...

Descripción completa

Detalles Bibliográficos
Autores principales: Quinn, Casey, Garrison, Louis P, Pownell, Anja K, Atkins, Michael B, de Pouvourville, Gérard, Harrington, Kevin, Ascierto, Paolo Antonio, McEwan, Phil, Wagner, Samuel, Borrill, John, Wu, Elise
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Position Article and Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359062/
https://www.ncbi.nlm.nih.gov/pubmed/32661115
http://dx.doi.org/10.1136/jitc-2020-000648

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359062/
https://www.ncbi.nlm.nih.gov/pubmed/32661115
http://dx.doi.org/10.1136/jitc-2020-000648

Ejemplares similares